Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactobacillus plantarum supernatant is a cell-free biologic preparation derived from the probiotic bacterium *Lactobacillus plantarum* (also known as *Lactiplantibacillus plantarum*). It is under investigation as a therapeutic agent for various conditions, including wound healing, cancer, and neuropsychiatric disorders. The supernatant contains a mixture of bioactive metabolites produced by the bacteria, such as lactic acid, antimicrobial peptides (bacteriocins), and phenolic compounds. Its proposed mechanisms of action include direct antimicrobial activity against pathogens like *E. coli* and *Staphylococcus aureus*, as well as antioxidant and anti-inflammatory effects, partly through the modulation of the NF-κB pathway. In oncology, it is being studied as a chemosensitizer in colorectal cancer. Research suggests it can restore sensitivity to butyrate-induced apoptosis in 5-fluorouracil-resistant cancer cells by upregulating the functional expression of the butyrate transporter SMCT1.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lactobacillus plantarum supernatant.